Early Access — free while we kick the tires
EdgarHawk

Saker Anwar Nusseibeh

CEO, Federated Hermes Limited

Officer

Latest: CEO, Federated Hermes Limited selling · June 2026

2 filings analyzed · 1 company · Latest 2026-06-09

Companies

Company Buys Sells Direction
FEDERATED HERMES, INC. FHI 0 3 Net selling

Activity

June 2026
medium
Sell
8,950 shares
$513,170
Significance 5/10

CEO Saker Anwar Nusseibeh sells 8,950 shares of FHI at $57.34, reducing holdings 5.6% to 151.3K shares

Saker Anwar Nusseibeh, CEO of Federated Hermes Limited, sold 8,950 shares at $57.34 on 2026-06-08 in an open-market transaction, reducing his holdings from 160.2K to 151.3K shares. At the current price of $57.64, the stock has appreciated 3.0% over the past 30 days and 1.5% over 90 days, trading -2.4% from its 52-week high of $59.05. Looking at his same-ticker history at FHI, prior sells on 2025-11-03 each saw the stock gain +5.6% and +3.9% respectively over the following 30 days, with neither sale preceding a decline over 90 days. His cross-ticker track record shows 3 prior open-market sells with an average 90-day return of +10.3% and a well-timed rate of 0.00%, indicating those sales consistently preceded stock appreciation rather than declines. The transaction occurs against a backdrop of solid fundamentals: FHI posted revenue of $479.0M in the latest quarter, net income of $96.4M, annual revenue growth of +10.3%, and a P/E of 11.24.

November 2025
medium
Sell
15,000 shares
$728,154
Significance 5/10

CEO Nusseibeh Saker Anwar sold 15,000 shares at blended average $48.54 on 2025-11-03; post-transaction holdings 157,039 shares.

CEO Nusseibeh Saker Anwar executed two separate sales totaling 15,000 shares (an 8.7% reduction in holdings) at an average price of $48.54, slightly below the current price of $49.06. The stock has declined 5.2% over 30 days and 4.6% over 90 days from the transaction date. At FHI specifically, his two prior open-market sales both showed negative 90-day returns (-7.4% and -6.2%), establishing a 100% well-timed rate on prior trades at this ticker. The company shows modest fundamentals with annual revenue growth of just 1.4% and a P/E of 15.19, suggesting a mature profile. While this sale reduced his equity stake, the timing pattern in his FHI history and the current price weakness warrant attention to whether this reflects informed positioning ahead of near-term headwinds.

Related insiders

Create a free account

Build watchlists, get email alerts on the tickers you follow, and read the full AI analysis on every insider filing.

Sign up — free during early access